Mueller Brian 4
4 · BIOMARIN PHARMACEUTICAL INC · Filed May 31, 2024
Insider Transaction Report
Form 4
Mueller Brian
EVP, Chief Financial Officer
Transactions
- Award
Common Stock
2024-04-30$68.65/sh+300$20,594→ 72,159 total - Exercise/Conversion
Common Stock
2024-05-30$63.10/sh+5,000$315,500→ 77,159 total - Sale
Common Stock
2024-05-30$75.19/sh−5,000$375,950→ 72,159 total - Exercise/Conversion
Stock Option (Right to Buy Common Stock)
2024-05-30−5,000→ 0 totalExercise: $63.10From: 2014-12-04Exp: 2024-06-03→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
- [F2]Trade made pursuant to a 10b5-1 plan executed on August 18, 2023.
- [F3]Reflects the number of options outstanding after the transactions from this specific stock option grant.